Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Altimmune, Inc. - Common Stock
(NQ:
ALT
)
4.760
-0.140 (-2.86%)
Streaming Delayed Price
Updated: 1:00 PM EDT, Jul 3, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Altimmune, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
July 03, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
July 01, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
June 30, 2025
Via
ACCESS Newswire
What to Expect from Altimmune's Earnings
May 12, 2025
Via
Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
June 28, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Benzinga Bulls And Bears: Nvidia, Micron, HIMS — And Markets Soar On Mideast And Tariff Relief
June 28, 2025
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
Via
Benzinga
Altimmune's Fatty Liver Candidate Faces Differentiation Doubts
June 27, 2025
Trucchio sees 48-week data as key for Phase 3 progress, while William Blair questions drug's impact on fibrosis and weight loss at 24 weeks.
Via
Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
June 26, 2025
Via
ACCESS Newswire
Top movers in Thursday's session
June 26, 2025
Wondering how the US markets performed one hour before the close of the markets on Thursday? Discover the movers and shakers of today's session in our comprehensive analysis.
Via
Chartmill
12 Health Care Stocks Moving In Thursday's Intraday Session
June 26, 2025
Via
Benzinga
Crude Oil Gains Over 1%; Walgreens Posts Upbeat Earnings
June 26, 2025
Via
Benzinga
Here are the top movers in Thursday's session.
June 26, 2025
Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Via
Chartmill
Gapping stocks in Thursday's session
June 26, 2025
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Thursday.
Via
Chartmill
Altimmune Stock Sinks After Mid-Stage Data From Fatty Liver Candidate
June 26, 2025
Altimmune's Phase 2b trial of pemvidutide showed significant MASH resolution, liver fat reduction, and favorable safety outcomes.
Via
Benzinga
Dow Surges 200 Points; US GDP Contracts 0.5%
June 26, 2025
Via
Benzinga
Topics
Stocks
Altimmune Stock Plummets After Mixed Results In Liver Disease Trial: Retail Sees ‘Nothing Of Substance’ To Start A Position
June 26, 2025
Up to 59.1% patients enrolled in the study achieved metabolic dysfunction-associated steatohepatitis resolution without worsening of fibrosis at 24 weeks, as compared to merely 19.1% for placebo.
Via
Stocktwits
Thursday's pre-market session: top gainers and losers
June 26, 2025
The US market session of Thursday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
Via
Chartmill
Altimmune, Bit Digital, Kratos Defense & Security Solutions And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
June 26, 2025
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
June 26, 2025
Via
Benzinga
Why Worthington Steel Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket
June 26, 2025
Via
Benzinga
Altimmune Stock Runs Hot Ahead Of MASH Trial Readout; Retail Bulls Eye Big Win
June 25, 2025
Traders are closely watching Thursday’s topline data for signs that pemvidutide could emerge as a competitive treatment in the growing MASH landscape.
Via
Stocktwits
Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside.
June 18, 2025
Via
The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
June 10, 2025
Via
Benzinga
Altimmune (ALT) Stock Rises Amid Clinical Trial Progress: What's Going On?
May 20, 2025
Altimmune stock rose on Tuesday without news, possibly due to high short interest. Its new trial for Alcohol Use Disorder and upcoming MASH results may be fueling excitement.
Via
Benzinga
Altimmune Reports Better-Than-Feared Q1 Loss, Secures $100M Credit Facility: Retail’s Pleased
May 13, 2025
In the second quarter, the firm expects to announce data from a phase 2 trial of its investigational therapy, Pemvidutide, in treating metabolic dysfunction-associated steatohepatitis (MASH).
Via
Stocktwits
10 Health Care Stocks Whale Activity In Today's Session
May 05, 2025
Via
Benzinga
What's Going On With Altimmune (ALT) Stock Today?
May 02, 2025
Altimmune shares jumped 8.5% on Friday. The stock is higher ahead of next week's presentation at the European Association for the Study of the Liver International Liver Congress.
Via
Benzinga
Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback?
April 30, 2025
Via
The Motley Fool
Earnings Scheduled For May 13, 2025
May 13, 2025
Via
Benzinga
What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday?
April 14, 2025
Pfizer ends danuglipron development after liver safety issue, boosting shares of Viking, Eli Lilly, and Novo Nordisk amid obesity drug competition.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.